Reviewing Tonix Pharmaceuticals (TNXP) and Echo Therapeutics (ECTE)
Tonix Pharmaceuticals (NASDAQ: TNXP) and Echo Therapeutics (OTCMKTS:ECTE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.
Valuation and Earnings
This table compares Tonix Pharmaceuticals and Echo Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tonix Pharmaceuticals||N/A||N/A||-$38.84 million||($4.77)||-0.75|
|Echo Therapeutics||$60,000.00||2.02||-$22.19 million||($1.10)||-0.01|
Insider and Institutional Ownership
17.5% of Tonix Pharmaceuticals shares are held by institutional investors. 4.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 7.0% of Echo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings and target prices for Tonix Pharmaceuticals and Echo Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Tonix Pharmaceuticals presently has a consensus price target of $8.33, suggesting a potential upside of 131.48%. Given Tonix Pharmaceuticals’ higher possible upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than Echo Therapeutics.
Risk and Volatility
Tonix Pharmaceuticals has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Echo Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
This table compares Tonix Pharmaceuticals and Echo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Echo Therapeutics beats Tonix Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The companys product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Echo Therapeutics Company Profile
Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.